KW 4490
Alternative Names: KW-4490Latest Information Update: 18 Dec 2008
Price :
$50 *
At a glance
- Originator Kyowa Hakko
- Class Antiasthmatics; Cyclohexanecarboxylic acids; Dioxanes
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 27 Sep 2004 Discontinued - Phase-II for Asthma in France (PO)
- 27 Sep 2004 Discontinued - Phase-II for Asthma in United Kingdom (PO)
- 15 Jun 2004 Phase-II clinical trials in Chronic obstructive pulmonary disease (unspecified route)